FDA 483 - LifeSouth Community Blood Centers, Inc. - August 19, 2021

During an FDA inspection of LifeSouth Community Blood Centers, Inc., located in Gainesville, FL, from August 17 to August 19, 2021, an initial observation was documented on a Form FDA 483. The primary concern involved the failure to maintain Red Blood Cells within the specified temperature range of 1 to 10 °C during shipment. Specifically, it was noted that apheresis concurrent Red Blood Cells were not consistently stored on ice from the point of collection until their arrival at the component processing facility, unless the arrival was anticipated to exceed a certain timeframe, deviating from standard operating procedures for single concurrent red cell units. However, a crucial aspect of this report is that this specific observation was subsequently removed by the FDA based on discussions held with the firm's management. A Form FDA 483 serves to notify a company of conditions or practices observed during an inspection that may indicate non-compliance with the Federal Food, Drug, and Cosmetic Act. While these observations typically warrant a firm's response detailing corrective actions, in this instance, the noted issue was clarified or resolved during the inspection, leading to its official retraction. This document therefore reflects the process of regulatory oversight and the dynamic nature of inspectional findings.